TY - JOUR
T1 - GPR146 Deficiency Protects against Hypercholesterolemia and Atherosclerosis
AU - BIOS Consortium
AU - Yu, Haojie
AU - Rimbert, Antoine
AU - Palmer, Alice E.
AU - Toyohara, Takafumi
AU - Xia, Yulei
AU - Xia, Fang
AU - Ferreira, Leonardo M.R.
AU - Chen, Zhifen
AU - Chen, Tao
AU - Loaiza, Natalia
AU - Horwitz, Nathaniel Brooks
AU - Kacergis, Michael C.
AU - Zhao, Liping
AU - Soukas, Alexander A.
AU - Kuivenhoven, Jan Albert
AU - Kathiresan, Sekar
AU - Cowan, Chad A.
N1 - Funding Information:
We express our gratitude to Jorge Plutzky for project discussion. We thank Lin Wu at Genome Modification Facility in Harvard University for generating Gpr146 −/− and Gpr146 fl/fl mice. We thank Curtis R. Warren and Max Friesen for generating the doxycycline-inducible expression plasmid. We thank Shunsuke Katsuki for sharing the protocol of atherosclerosis analysis. We also thank Junghyun Lee and Yujia Shen for proofreading the manuscript. This work was funded by the National Institutes of Health ( NHLBI/R33HL120781 and NIDDK/R01DK097768 to C.A.C.), the Nutrition Obesity Research Center of Harvard ( P30DK040561 to C.A.C. and A.A.S.), the Netherlands CardioVascular Research Initiative and the Established Investigator of the Netherlands Heart Foundation ( CVON2017-2020 ; 2015T068 to J.A.K.) and Institut de France-Fondation Lefoulon-Delalande Postdoctoral Fellowship (to A.R.).
Funding Information:
We express our gratitude to Jorge Plutzky for project discussion. We thank Lin Wu at Genome Modification Facility in Harvard University for generating Gpr146−/− and Gpr146fl/fl mice. We thank Curtis R. Warren and Max Friesen for generating the doxycycline-inducible expression plasmid. We thank Shunsuke Katsuki for sharing the protocol of atherosclerosis analysis. We also thank Junghyun Lee and Yujia Shen for proofreading the manuscript. This work was funded by the National Institutes of Health (NHLBI/R33HL120781 and NIDDK/R01DK097768 to C.A.C.), the Nutrition Obesity Research Center of Harvard (P30DK040561 to C.A.C. and A.A.S.), the Netherlands CardioVascular Research Initiative and the Established Investigator of the Netherlands Heart Foundation (CVON2017-2020; 2015T068 to J.A.K.) and Institut de France-Fondation Lefoulon-Delalande Postdoctoral Fellowship (to A.R.). Conceptualization, H.Y. and C.A.C.; Methodology, H.Y. J.A.K. S.K. and C.A.C.; Formal Analysis, H.Y. A.R. J.A.K. and C.A.C.; Investigation, H.Y. A.R. A.E.P. Y.X. T.T, F.X. L.M.R.F. Z.C. T.C. N.L. N.B.H. M.C.K. L.Z. A.A.S. J.A.K. and C.A.C.; Writing-Original Draft, H.Y. and C.A.C.; Writing-Review & Editing, H.Y. N.B.H. and C.A.C.; Visualization, H.Y. and C.A.C.; Supervision, C.A.C.; Funding Acquisition, C.A.C. C.A.C. is a founder of CRISPR Therapeutics and Sana Biotechnology. S.K. is a founder of Maze Therapeutics, Verve Therapeutics, and San Therapeutics.
Publisher Copyright:
© 2019 Elsevier Inc.
PY - 2019/11/27
Y1 - 2019/11/27
N2 - Although human genetic studies have implicated many susceptible genes associated with plasma lipid levels, their physiological and molecular functions are not fully characterized. Here we demonstrate that orphan G protein-coupled receptor 146 (GPR146) promotes activity of hepatic sterol regulatory element binding protein 2 (SREBP2) through activation of the extracellular signal-regulated kinase (ERK) signaling pathway, thereby regulating hepatic very low-density lipoprotein (VLDL) secretion, and subsequently circulating low-density lipoprotein cholesterol (LDL-C) and triglycerides (TG) levels. Remarkably, GPR146 deficiency reduces plasma cholesterol levels substantially in both wild-type and LDL receptor (LDLR)-deficient mice. Finally, aortic atherosclerotic lesions are reduced by 90% and 70%, respectively, in male and female LDLR-deficient mice upon GPR146 depletion. Taken together, these findings outline a regulatory role for the GPR146/ERK axis in systemic cholesterol metabolism and suggest that GPR146 inhibition could be an effective strategy to reduce plasma cholesterol levels and atherosclerosis.
AB - Although human genetic studies have implicated many susceptible genes associated with plasma lipid levels, their physiological and molecular functions are not fully characterized. Here we demonstrate that orphan G protein-coupled receptor 146 (GPR146) promotes activity of hepatic sterol regulatory element binding protein 2 (SREBP2) through activation of the extracellular signal-regulated kinase (ERK) signaling pathway, thereby regulating hepatic very low-density lipoprotein (VLDL) secretion, and subsequently circulating low-density lipoprotein cholesterol (LDL-C) and triglycerides (TG) levels. Remarkably, GPR146 deficiency reduces plasma cholesterol levels substantially in both wild-type and LDL receptor (LDLR)-deficient mice. Finally, aortic atherosclerotic lesions are reduced by 90% and 70%, respectively, in male and female LDLR-deficient mice upon GPR146 depletion. Taken together, these findings outline a regulatory role for the GPR146/ERK axis in systemic cholesterol metabolism and suggest that GPR146 inhibition could be an effective strategy to reduce plasma cholesterol levels and atherosclerosis.
KW - ERK1/2
KW - SREBP2 pathway
KW - atherosclerosis
KW - hypercholesterolemia
KW - orphan G protein-coupled receptor 146
UR - http://www.scopus.com/inward/record.url?scp=85075509227&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85075509227&partnerID=8YFLogxK
U2 - 10.1016/j.cell.2019.10.034
DO - 10.1016/j.cell.2019.10.034
M3 - Article
C2 - 31778654
AN - SCOPUS:85075509227
SN - 0092-8674
VL - 179
SP - 1276-1288.e14
JO - Cell
JF - Cell
IS - 6
ER -